Sign up
CRBP

Corbus Pharmaceuticals Holding (NASDAQ: CRBP)

Healthcare · Biotechnology

$2.75−0.27 (−8.80%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. CRBP fell 8.80% in the Nov 18 session to $2.75, which is 77.4% below its 52-week high of $12.15. Six active firms cover the stock as of Nov 19, 2026; six active firms with targets average $37.50 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 41.3 (overbought above 70, oversold below 30)

Trend—

—

Short interest—

—

CRBP price chart

Price $2.75 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$2.96Nov 18, 2026 session
Previous close
$3.01Nov 17, 2026 close
Day range
$2.62 – $3.00Nov 18, 2026 session
52-week range
$2.75 – $12.15Through Nov 18, 2026
Volume
632.70KNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$69.86M
P/E (TTM)negative earnings —
Forward P/E—
EPS (TTM)−$6.04
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)2.85

Price history

CRBP · nasdaq · USD

Last completed session: Nov 18, 2026

Split-adjusted · volume in shares

November 2026 · 13 completed sessions
DateOpenHighLowCloseChangeVolume
2.963.00292.622.745−0.265−8.803987%630,362
Open 2.96High 3.0029Low 2.62
3.293.342.95253.01−0.365−10.814815%570,863
Open 3.29High 3.34Low 2.9525
3.413.623.003.375−0.015−0.442478%953,696
Open 3.41High 3.62Low 3.00
3.383.533.273.39−0.02−0.58651%575,119
Open 3.38High 3.53Low 3.27
4.004.013.23013.41−0.59−14.75%1,050,996
Open 4.00High 4.01Low 3.2301
4.044.203.804.00+0.07+1.78117%672,732
Open 4.04High 4.20Low 3.80
3.393.983.213.93+0.41+11.647727%645,629
Open 3.39High 3.98Low 3.21
3.113.7453.113.52+0.45+14.65798%1,247,576
Open 3.11High 3.745Low 3.11
2.933.1252.913.07+0.21+7.342657%685,228
Open 2.93High 3.125Low 2.91
3.573.572.812.86−0.71−19.887955%1,356,435
Open 3.57High 3.57Low 2.81
3.974.09923.573.57−0.30−7.751938%2,012,725
Open 3.97High 4.0992Low 3.57
3.924.113.733.87−0.045−1.149425%4,367,646
Open 3.92High 4.11Low 3.73
4.214.233.8953.915−0.305−7.227488%674,178
Open 4.21High 4.23Low 3.895

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

— · Quantellect signals not available

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
6Buy
0Neutral
0Sell
0Strong Sell

Based on 6 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$30.00
Average$37.50
High$48.00

As of Nov 19, 2026 across 6 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$1.27−$1.81—
Q2 2026—−$1.81—
Q1 2026—−$1.23—
Annual 2025—−$5.90—
Q3 2025—−$1.90—
Q2 2025—−$1.44—
Q1 2025—−$1.39—
Annual 2024−$1.26−$3.68—

Smart-money activity

In the last 60 days: 1 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellCormorant Asset Management, LP / Cormorant Global Healthcare Master Fund, LP / Chen BihuaSell$1.7MForm 4
Insider sellBen YongSell$15.7KForm 4
Insider buySaxena Nishant CBuy$25.0KForm 4
Insider sellCohen YuvalSell$171.4KForm 4
Insider sellMoran Sean F.Sell$121.0KForm 4
Insider sellKung WinstonSell$16.0KForm 4
Insider sellJenkins John KennethSell$38.0KForm 4
Insider sellAltmeyer AnneSell$19.1KForm 4
Insider buySaxena Nishant CBuy$68.2KForm 4
Insider buySaxena Nishant CBuy$33.0KForm 4
All smart-money activity →

News and press releases

News and press releases are not available.

All CRBP news →

Company profile

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

CEO
Dr. Yuval Cohen Ph.D.
Headquarters
Norwood, MA, United States
Employees
36
IPO date
Nov 11, 2014
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.